If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Kisunla ™ (donanemab-azbt) injection, for intravenous infusion
350 mg/20 mL (17.5 mg/mL)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Which Alzheimer's disease treatment registries and/or programs are currently enrolling?
Currently enrolling studies and programs are listed below.
See important safety information, including boxed warning, in the attached prescribing information.
AD Registry Information in Donanemab Prescribing Information
Providers should encourage patients to participate in real world data collection (eg, registries) to help further the understanding of Alzheimer's disease (AD) and the impact of AD treatments. Providers and patients can contact 1-800-LillyRx (1-800-545-5979) for a list of currently enrolling programs.1
Current Enrolling Studies and Programs
Alzheimer's Disease Treatment Registries and Programs provides a list of studies and programs that are currently enrolling. This listing is current at the time of writing. The list of studies can also be found here.
Study Title |
Sponsor |
Clinicaltrials.gov number |
Contact Information |
Alzheimer's National Registry for Treatment and Diagnostics |
Alzheimer's Disease and Related Disorders Association, Inc |
Phone: 215-574-3181 ext 4181 Email: alz-net@acr.org |
|
Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry |
Emory University |
Phone: 404-727-3509 Email: jlah@emory.edu |
|
A Prospective Comparative Study of Monoclonal Antibodies for the Treatment of Alzheimer's Disease |
Beth Israel Deaconess Medical Center |
Phone: 617-667-4074 Email: dpress@bidmc.harvard.edu |
|
Prospective Study on Anti-Amyloid-β Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease Coverage of Evidence Development |
Centers for Medicare and Medicaid Services |
Phone: 410-786-2281 Email: CMS_caginquiries@cms.hhs.gov |
Enclosed Prescribing Information
References
1Kisunla [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.
2Monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease (AD). Centers for Medicare & Medicaid Services. Accessed June 25, 2024. https://www.cms.gov/medicare/coverage/coverage-evidence-development/monoclonal-antibodies-directed-against-amyloid-treatment-alzheimers-disease-ad
Date of Last Review: June 25, 2024